HKU Gets Green Light For Nasal Covid Vaccine Trials
"); jQuery("#212 h3").html("
"); });
2020-09-09 HKT 19:19
Share this story
The University of Hong Kong says mainland authorities have allowed clinical trials of a nasal spray vaccine for Covid-19 it has been developing with mainland institutions.
The State Key Laboratory of Emerging Infectious Diseases of the university's Department of Microbiology has been working on the vaccine with Xiamen University and Beijing Wantai Biological Pharmacy.
It says it is the only nasally-administered vaccine against the disease to be allowed for clinical trials so far by the National Medical Products Administration.
Future Fintechs Hong Kong Subsidiary Seeks VASP And Asset Management Licenses
Future Fintech, a financial and digital technology services provider, announced that its wholly owned Hong Kong subsidi... Read more
Can Regulation Scale With Innovation? Inside The Stablecoin Plans Of HK And The U.S.
Back in 2022, stablecoins were still an emerging topic. Yet, they stirred enough flurry for the Hong Kong Monetary Auth... Read more
Cyberport Start-ups Forge Regional Fintech Ties At MyFintech Week 2025 In Malaysia
Cyberport led a delegation of its fintech start-ups to MyFintech Week 2025 (MyFW 2025), held in Kuala Lumpur from 4 to ... Read more
Hong Kongs Stablecoin Law Triggers Industry Concerns Over KYC Rules
Hong Kong’s newly implemented stablecoin law, in effect since 1 August, has sparked concern among some in the industr... Read more
Stopping Fraud At The Gate: The New Imperative For Registration & Transaction Monitoring
The Asia-Pacific fintech landscape is thriving, fueled by the rapid adoption of digital payments, online banking and al... Read more
Hong Kong Private Banks See 14% Growth, Hire 400 More Wealth Managers
Hong Kong’s private banking and wealth management sectors are poised for further growth in hiring and office expansio... Read more